MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.
GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]
Bridging the Gap: Streamlining iPSC-Derived Cell Line Development from Donor Cells to MCB
Allogeneic iPSC-derived therapies hold immense promise, offering scalable, off-the-shelf solutions for a wide spectrum of diseases. However, the journey from donor cells to a gene edited, clinically compliant GMP Master Cell Bank (MCB) is fraught with challenges and is particularly vulnerable to risks stemming from misaligned early development.
A major bottleneck seen in the majority of iPSC therapeutic programs arises when development teams continue to rely on R&D grade cell lines to confirm proof-of-concept, conduct preclinical animal studies, and to start process & analytical development. [Read more…]
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. [Read more…]
BBG Advanced Therapies collects first cell donation on one-of-a-kind bus
New vehicle to help enable lifesaving new advanced therapies
The world’s only mobile leukapheresis center recorded its first donation on Monday, Oct. 20, marking the beginning of a new era for global healthcare.
The BBG Advanced Therapies mobile leukapheresis center, the first of its kind in the world, can help improve access to lifesaving treatments across an area of almost 70,000 square miles currently underserved by next-generation advanced therapies. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 18
- Next Page »